Discover 1,022 paid clinical trials in Stamford, Connecticut. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,022
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
for
Castration-Resistant Prostate Carcinoma,
Location: Stamford CT, New York NY, Hackensack NJ, Springfield MA,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT06632977
Phase2, Recruiting
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Location: Stamford CT, Greenwich CT, Harrison NY, Mount Kisco NY,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT06661720
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
for
Non Small Cell Lung Cancer
Location: Stamford CT, White Plains NY, Stony Brook NY,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06312137
Phase3, Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
for
Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
Location: Stamford CT, Philadelphia PA, Milford MA, Foxborough MA,
Sponsor: Dana-Farber Cancer Institute
Sex: All
Age: 18+
Code: NCT04468061
Phase2, Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
for
Triple Negative Breast Cancer
Location: Stamford CT, White Plains NY, Lake Success NY,
Sponsor: Gilead Sciences
Sex: All
Age: 18+
Code: NCT05633654
Phase3, Recruiting
ATEMPT 2.0: Adjuvant T-DM1 vs TH
for
Breast Cancer, HER2-positive Breast Cancer
Location: Stamford CT, Long Ridge CT, Greenwich CT, Fairfield CT,
Sponsor: Dana-Farber Cancer Institute
Sex: All
Age: 18+
Code: NCT04893109
Phase2, Recruiting
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
for
AL Amyloidosis
Location: Stamford CT, Greenwich CT, Harrison NY, Trumbull CT,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT06022939
Phase3, Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Location: Stamford CT, Greenwich CT, Norwalk CT, Harrison NY,
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT05256225
Phase3, Recruiting
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
for
Gastric Adenocarcinoma,
Location: Stamford CT, Greenwich CT, East White Plains NY,
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All
Age: 18+
Code: NCT07001748
Phase2, Phase3, Recruiting
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab